Gensco Laboratories LLC, operating as Gensco Pharma, has announced the acquisition of global rights and intellectual property for RizaFilm and RizaPort, the first and only rizatriptan oral dissolvable film (ODF) therapy developed specifically for migraine treatment. The innovative formulation, which has already secured approvals from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), is set to launch in the United States by Q4 2025.
The acquisition represents a significant strategic move for Gensco Pharma as it expands its footprint in the specialty pharmaceuticals market. The company is currently ramping up manufacturing capabilities to prepare for the U.S. market entry while simultaneously engaging in licensing discussions to expand availability in international markets including China, India, the Middle East, and the Americas.
Novel Approach to Migraine Treatment
RizaFilm and RizaPort utilize Gensco's proprietary oral dissolving film formulation of rizatriptan benzoate, offering a distinct advantage over traditional tablet medications. The film dissolves rapidly in the mouth without requiring water, addressing key patient needs for convenience, portability, and faster relief.
The EMA has approved the treatment for patients aged 6 and older, while FDA approval currently includes patients aged 6-11, with expanded age ranges planned at launch. This formulation is particularly beneficial for patients experiencing migraine-associated symptoms such as nausea, photophobia, and phonophobia.
"We are excited to bring RizaFilm to market under Gensco's leadership to deliver a consistent, high-quality and convenient treatment for patients in need," said Paul Zimmerman, MD, CEO of Gensco Pharma. "This acquisition solidifies our commitment to providing innovative solutions for migraine sufferers, and positions Gensco as a key player in the migraine treatment space."
Market Opportunity and Strategic Positioning
The global migraine drugs market presents a substantial opportunity for Gensco Pharma. Valued at approximately $5.65 billion in 2023, the market is projected to reach nearly $11 billion by 2030, with a compound annual growth rate of 15.6%.
Migraine represents a significant health burden globally. According to the American Migraine Foundation, approximately 42 million Americans suffer from migraines, making it the second leading cause of disability nationwide. The World Health Organization reports that around 40% of the global population—approximately 3.1 billion individuals—were affected by migraine and other headache disorders in 2021.
Gensco's pricing strategy aims to ensure RizaFilm will be affordable globally, making the treatment accessible to patients worldwide. The company's approach addresses a critical gap in the current treatment landscape, where many patients struggle with traditional tablet formulations, particularly when experiencing nausea during migraine attacks.
Manufacturing and Distribution Plans
With FDA and EMA approvals already secured, Gensco Pharma is actively preparing for commercial distribution. The company is establishing a global supply chain to support both the U.S. launch and international expansion efforts.
The oral dissolvable film technology represents an advancement in drug delivery systems, aligning with Gensco's focus on innovative pharmaceutical solutions. By eliminating the need for water, RizaFilm offers patients the ability to take their medication discreetly and conveniently, potentially improving treatment adherence and outcomes.
About Gensco Pharma
Gensco is a specialty pharmaceutical company focused on the development and commercialization of both prescription and over-the-counter products. Based in Miami, Florida, the company leverages its expertise in innovative drug delivery systems to introduce products that improve patient outcomes.
With a strong commitment to research and development, Gensco targets significant niche markets with high unmet medical needs. The acquisition of RizaFilm and RizaPort aligns with the company's mission to provide solutions that genuinely improve the patient experience while addressing substantial market opportunities.
As Gensco Pharma continues to expand its portfolio and global reach, the company remains dedicated to developing pharmaceutical innovations that address the unique challenges faced by patients worldwide.
